The ADAM17 inhibitor ZLDI-8 sensitized hepatocellular carcinoma cells to sorafenib through Notch1-integrin β-talk

The ADAM17 inhibitor ZLDI-8 sensitized hepatocellular carcinoma cells to sorafenib through Notch1-integrin β-talk

ZLDI-8 is an A disintegrin and metalloproteinase domain 17 (ADAM17) inhibitor that suppresses the shedding of Notch1 to the Notch1 intracellular domain (NICD). In previous studies, we found that ZLDI-8 was able to sensitize HCC to sorafenib, but the mechanism of action remains unclear. The sensitizi...

Full description

Bibliographic Details
Main Authors: Chang Xu, Xudong Gao, Tianshu Ren, Hefeng Geng, Kaisi Yang, Yaoguang Huang, Weige Zhang, Shanbo Hou, Aigang Song, Yingshi Zhang, Qingchun Zhao
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:Pharmacological Research
Subjects:
Notch1
Integrinβ
ILK
Sorafenib
Crosstalk
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661824000860

Internet

http://www.sciencedirect.com/science/article/pii/S1043661824000860

Similar Items